Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options
Alimuddin Zumla1, Ziad A Memish2, Markus Maeurer3
1Division of Infection and Immunity, University College London, London, UK; NIHR Biomedical Research Centre, University College London Hospitals, London, UK; University of Zambia-University College London Research and Training Project, University Teaching Hospital, Lusaka, Zambia; Global Center for Mass Gatherings Medicine, Ministry of Health, Riyadh, Saudi Arabia.
Abstract:
The emergence and spread of antimicrobial-resistant bacterial, viral, and fungal pathogens for which diminishing treatment options are available is of major global concern. New viral respiratory tract infections with epidemic potential, such as severe acute respiratory syndrome, swine-origin influenza A H1N1, and Middle East respiratory syndrome coronavirus infection, require development of new antiviral agents. The substantial rise in the global numbers of patients with respiratory tract infections caused by pan-antibiotic-resistant Gram-positive and Gram-negative bacteria, multidrug-resistant Mycobacterium tuberculosis, and multiazole-resistant fungi has focused attention on investments into development of new drugs and treatment regimens. Successful treatment outcomes for patients with respiratory tract infections across all health-care settings will necessitate rapid, precise diagnosis and more effective and pathogen-specific therapies. This Series paper describes the development and use of new antimicrobial agents and immune-based and host-directed therapies for a range of conventional and emerging viral, bacterial, and fungal causes of respiratory tract infections.
Insights
Antimicrobial resistance is a global threat, necessitating new treatments for bacterial, viral, and fungal respiratory infections. This paper reviews novel antimicrobial agents and therapies to combat these challenging pathogens.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Antimicrobial resistance (AMR) poses a significant global health challenge, limiting treatment options for bacterial, viral, and fungal respiratory tract infections.
- Emerging viral infections and the rise of pan-antibiotic-resistant bacteria, multidrug-resistant Mycobacterium tuberculosis, and multiazole-resistant fungi necessitate urgent development of new therapeutic strategies.
- Effective management of respiratory tract infections requires rapid diagnostics and targeted therapies.
Purpose of the Study:
- To review the development and application of novel antimicrobial agents for respiratory pathogens.
- To explore immune-based and host-directed therapies for treating respiratory tract infections.
- To address the challenge of antimicrobial resistance in bacterial, viral, and fungal respiratory infections.
Main Methods:
- Literature review of recent advancements in antimicrobial drug development.
- Analysis of immune-based and host-directed therapeutic strategies.
- Synthesis of information on emerging and conventional respiratory pathogens.
Main Results:
- Development of new antimicrobial agents is crucial for combating resistant pathogens.
- Novel therapeutic approaches, including immune-based and host-directed therapies, show promise.
- Pathogen-specific treatments are essential for successful patient outcomes.
Conclusions:
- Addressing the global threat of antimicrobial resistance requires continuous innovation in drug development and therapeutic strategies.
- New antimicrobial agents and advanced therapies are vital for managing complex respiratory tract infections.
- Integrated approaches combining diagnostics and targeted therapies are key to improving patient care.
More Related Videos
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
11:15Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Microbiota of the Respiratory Tract
Development of Antibiotic Resistance
